BRIDGING THE GAP BETWEEN SCIENCE AND PATIENTS

2 to 4 novel antibiotics by 2030

overlay

The growing threat of AMR

The world is losing its most powerful tool in healthcare: antibiotics.

The reason: rapidly rising antibiotic-resistant infections – also called antimicrobial resistance, or AMR.

These infections can affect anyone, of any age, in any country. AMR is a universal issue that impacts us all – we are all at risk.

Antibiotic resistance undermines every aspect of medicine today. We rely on the availability of effective antibiotics to be able to do everything from wisdom tooth extractions to organ transplantation to cancer chemotherapy.

The fragile antibiotic pipeline is close to collapse

Despite the huge societal costs of AMR, there is no viable market for new antibiotics and therefore little funding available to support clinical research.

As a result, important antibiotics in the early stages of development may never get over the “valley of death” to reach patients.

Bridging the gap

$1

The ground-breaking AMR Action Fund expects to invest more than US$1 billion to bridge the funding gap and respond to the AMR threat.

2-4

The Fund aims to bring 2-4 new antibiotics to market this decade that will save patient lives.

The concept of the AMR Action Fund has been developed in collaboration with the World Health Organization, the European Investment Bank, and the Wellcome Trust. It aims to overcome key technical and funding barriers of late-stage antibiotic development and will work with governments to ensure there is a sustainable pipeline of new antibiotics to fight superbugs.

Together, we must act now to safeguard our future from this global threat.

Our Investors

View Website
View Website
View Website
View Website
View Website
View Website
View Website
View Website
View Website
View Website
View Website
View Website
View Website
View Website
View Website
View Website
View Website
View Website
View Website
View Website
View Website
View Website
View Website
View Website
AMR is a slow tsunami that threatens to undo a century of medical progress. I very much welcome this new engagement of the private sector in the development of urgently-needed antibacterial treatments. WHO looks forward to working with the AMR Action Fund to accelerate research to address this public health crisis.
— Dr Tedros Adhanom Ghebreyesus
Director General World Health Organization
EIB is actively supporting identified market failures with innovative financial instruments, antimicrobial resistance is clearly one. We welcome the opportunity to join forces with public and private actors, such as the pharmaceutical industry, philanthropic funders, multilateral development banks, and the World Health Organization to tackle this threat. The initiative is aligned with the EIB’s core objectives in health and we are proud to be part of the origination group of the new AMR Action Fund.
— Werner Hoyer
President, European Investment Bank
My 18-month-old son Simon woke up one morning screaming in agony. Within 24 hours, he died from a drug-resistant infection that doctors were powerless to stop. Had effective antibiotics been available, he would still be with us today. For the first time in years, there is real hope on the horizon. The fund’s investment in new antibiotics will provide funding for the sorts of lifesaving treatments that could have saved my son.
— Everly Macario
Public Health Advocate

An Industry-led Fund

The pharmaceutical industry, in collaboration with the WHO, EIB, and the Wellcome Trust, came together to design the AMR Action Fund. So far, over 20 leading pharmaceutical companies have pledged to invest nearly US$1 billion through the new AMR Action Fund.

The AMR Action Fund will bridge innovative candidates in the pipeline through the most challenging later stages of drug development, ultimately providing governments time to make the necessary policy reforms to enable a sustainable antibiotic pipeline.

The AMR Action Fund expects to invest more than US$1 billion with the support of future partners, such as philanthropies, development banks and multilateral organizations. It will form one of the largest collective ventures ever set up to address AMR.

@saveantibiotics: “Unlike #COVID19, which came along suddenly and burst on the scene, the #superbug crisis has been simmering along,” @chngin_the_wrld explains. https://t.co/aUtNoFYbRk

- October 8, 2020

@IFPMA: During a @ChathamHouse webinar with @rosswrite_SW1, @ThomasCueni was joined by Lord Jim O’Neill, @CARB_X's @koutterson, and @gardp_amr's @LauraPiddock, discussing the urgent need to develop antibiotics & efforts to address the #AMR funding gap https://t.co/77LNMOSqWc https://t.co/qo2i6Kngp3

- October 8, 2020

Let's turn the question mark at the end of the title to an exclamation point! https://t.co/XZxidBW4sM

- October 8, 2020

@koutterson: Hill briefing on preparedness for the growing problem of drug-resistant bacteria - Thursday Oct. 8, 3pm ET sponsored by @ThePFID @WeFightAMR https://t.co/E9IjHSW2tK

- October 8, 2020

@WeFightAMR: “The 6th annual World Antimicrobial Resistance Congress will be held virtually October 8-9, 2020. It will showcase more than 250 presentations, including speakers from @CARB_X funded companies, @ForgeThera and @Entasistx.”
https://t.co/8RDiIGPZdV

- October 8, 2020

@Wellcome_AMR: It's nearly time for our 2nd webinar, this time looking at preventing infections. What can we learn from COVID and apply to AMR?

Hear from: @ASPphysician, @lindsaymdenny, @SouthAfricanASP, Ben Park & Padmini Srikantiah

When: 15/10/2020

Register 👉https://t.co/kHnor3Yk4W https://t.co/KEGZa1C6hP

- October 8, 2020